Effects on sexual function in Japanese patients with benign prostatic hyperplasia upon switching from combination therapy with α1 blocker and dutasteride to combination therapy with tadalafil and dutasteride

References

• Sarma AV, Wei JT. Clinical practice. Benign prostatic hyperplasia and lower urinary tract symptoms. N Engl J Med. 2012;367:248–257.
   PubMed Web of Science ®Google Scholar
• Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099–1109.
   PubMed Web of Science ®Google Scholar
• Chua ME, Mendoza J, See M, IV, et al. A critical review of recent clinical practice guidelines on the diagnosis and treatment of non-neurogenic male lower urinary tract symptoms. Can Urol Assoc J. 2015;9:463–470.
   Web of Science ®Google Scholar
• Lin KH, Lin YW, Wen YC, et al. Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia. Aging Male. 2012;15:246–252.
   PubMed Web of Science ®Google Scholar
• Favilla V, Russo GI, Privitera S, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male. 2016;19:175–181.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57:123–131.
   PubMed Web of Science ®Google Scholar
• Hagberg KW, Divan HA, Persson R, et al. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. Br Med J. 2016;354:i4823.
   PubMed Web of Science ®Google Scholar
• Gacci M, Andersson KE, Chapple C, et al. Latest evidence on the use of phosphodiesterase type 5 inhibitors for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2016;70:124–133.
   PubMed Web of Science ®Google Scholar
• Amano T, Earle C, Imao T, et al. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. Aging Male. 2018;21:77–82.
   PubMed Web of Science ®Google Scholar
• Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2011;60:809–825.
   PubMed Web of Science ®Google Scholar
• Casabe A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191:727–733.
   PubMed Web of Science ®Google Scholar
• Park HJ, Park NC. Combination therapy with dutasteride and tadalafil in men with moderate-to-severe benign prostatic hyperplasia. Eur Urol Suppl. 2013;12:e1092.
   Google Scholar
• Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822–830.
   PubMed Web of Science ®Google Scholar
• Mulhall JP, Goldstein I, Bushmakin AG, et al. Validation of the erection hardness score. J Sex Med. 2007;4:1626–1634.
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJ, O’Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549–1557.
   PubMed Web of Science ®Google Scholar
• Homma Y, Yoshida M, Seki N, et al. Symptom assessment tool for overactive bladder syndrome-overactive bladder symptom score. Urology 2006;68:318–323.
   PubMed Web of Science ®Google Scholar
• WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157–163.
   PubMed Web of Science ®Google Scholar
• La Torre A, Giupponi G, Duffy D, et al. Sexual dysfunction related to drugs: a critical review. Part V: α-blocker and 5-ARI drugs. Pharmacopsychiatry 2016;49:3–13.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47:824–837.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434–441.
   PubMed Web of Science ®Google Scholar
• Masumori N, Tsukamoto T, Kumamoto Y, et al. Decline of sexual function with age in Japanese men compared with American men-results of two community-based studies. Urology 1999;54:335–344.
   PubMed Web of Science ®Google Scholar
• Terai A, Ichioka K, Matsui Y, et al. Association of lower urinary tract symptoms with erectile dysfunction in Japanese men. Urology. 2004;64:132–136.
   PubMed Web of Science ®Google Scholar
• Derby CA, Mohr BA, Goldstein I, et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56:302–306.
   PubMed Web of Science ®Google Scholar
• Fwu CW, Kirkali Z, McVary KT, et al. Cross-sectional and longitudinal associations of sexual function with lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2015;193:231–238.
   PubMed Web of Science ®Google Scholar
• Porst H, Oelke M, Goldfischer ER, et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology. 2013;82:667–673.
   PubMed Web of Science ®Google Scholar
• Maeda T, Kikuchi E, Hasegawa M, et al. A prospective longitudinal survey of erectile function status in symptomatic benign prostatic hyperplasia patients treated with dutasteride. Aging Male. 2016;19:111–116.
   PubMed Web of Science ®Google Scholar
• Canguven O, Talib RA, El Ansari W, et al. Vitamin D treatment improves levels of sexual hormones, metabolic parameters and erectile function in middle-aged vitamin D deficient men. Aging Male. 2017;20:9–16.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Konaka H, Ijima M, et al. The correlation between highly sensitive C-reactive protein levels and erectile function among men with late-onset hypogonadism. Aging Male. 2016;19:239–243.
   PubMed Web of Science ®Google Scholar
• Amano T, Imao T, Takemae K, et al. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male. 2010;13:242–246.
   PubMed Web of Science ®Google Scholar
• Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4:1708–1712.
   PubMed Web of Science ®Google Scholar